CRISPR Gene Editing Reaches First Clinical Use Outside the US in Bahrain

A MedCram expert-analysis video examines CRISPR gene editing, in which guide RNA directs Cas9 to cut a target DNA sequence and correct disease-causing genes such as the defective gene in sickle cell disease. The FDA approved the first gene therapies for sickle cell disease in late 2023, and the technology has now been applied clinically for the first time outside the United States, in the Kingdom of Bahrain. The discussion covers how the mechanism works and why access matters in regions where sickle cell disease and thalassemia are common.